Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolinza in acute myeloid leukemia
NCT00305773Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2006
- Primary completion
- May 2009
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Jan 2006; status: completed.
02
Drugs
vorinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00305773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305773.